PAI
PYXS icon

Palo Alto Investors’s Pyxis Oncology PYXS Stock Holding History

Palo Alto Investors’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.6M Sell
864,277
-146,233
-14% -$280K 0.36% 35
2026
Q1 		$1.48M Sell
1,010,510
-26,911
-3% -$40.6K 0.23% 40
2025
Q4 		$1.19M Hold
1,037,421
– – 0.17% 40
2025
Q3 		$2.3M Hold
1,037,421
– – 0.43% 34
2025
Q2 		$1.14M Hold
1,037,421
– – 0.24% 36
2025
Q1 		$1.02M Hold
1,037,421
– – 0.19% 36
2024
Q4 		$1.62M Buy
1,037,421
+867,421
+510% +$2.5M 0.25% 30
2024
Q3 		$624K Buy
+170,000
New +$595K 0.08% 41

Other funds holding PYXS

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Palo Alto Investors's PYXS Position: Q2 2026 in Review

Palo Alto Investors reduced its Pyxis Oncology (PYXS) stake by 14% in Q2 2026, selling an estimated $280K and leaving 864,277 shares worth $2.6M. The position accounts for 0.36% of the portfolio, ranked #35.

Palo Alto Investors first reported a position in PYXS in Q3 2024 and has held it in 8 quarters since. 76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • Palo Alto Investors held 864,277 shares of Pyxis Oncology worth $2.6M as of Q2 2026.
  • Palo Alto Investors sold 146,233 Pyxis Oncology shares in Q2 2026, an estimated $280K.
  • Pyxis Oncology made up 0.36% of Palo Alto Investors's portfolio in Q2 2026, its #35 holding.
  • Palo Alto Investors first reported a position in Pyxis Oncology in Q3 2024 and has held it in 8 quarters since.
  • 76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Palo Alto Investors's 13F filing for Q2 2026, filed 17 Aug 2026.